• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    BioRestorative Therapies And 3 Other Stocks Under $3 Insiders Are Buying

    9/1/23 9:08:35 AM ET
    $BRTX
    $COEP
    $RWLK
    $TLS
    Managed Health Care
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $BRTX alert in real time by email

    The Dow Jones closed lower by over 150 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

    Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.

    BioRestorative Therapies

    • The Trade: BioRestorative Therapies, Inc. (NASDAQ:BRTX) Director, VP of Research and Development Francisco Silva acquired a total of 4,954 shares an average price of $2.22. To acquire these shares, it cost around $10,998.
    • What’s Happening: BioRestorative Therapies announced a $2.1 million registered direct offering.
    • What BioRestorative Therapies Does: BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, primarily involving adult (non-embryonic) stem cells.

    Telos

    • The Trade: Telos Corporation (NASDAQ:TLS) Chairman and CEO John B Wood acquired a total of 120,187 shares at an average price of $2.20. The insider spent around $263,907.
    • What’s Happening: Telos was awarded a five-year contract with Defense Information Systems Agency.
    • What Telos Does: Telos Corp offers technologically advanced, software-based security solutions that empower and protect the world's security-conscious organizations against rapidly evolving, sophisticated and pervasive threats.

    Coeptis Therapeutics

    • The Trade: Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) Director Chris Calise acquired a total of 11,582 shares at an average price of $0.94. To acquire these shares, it cost around $10,879.
    • What’s Happening: Coeptis Therapeutics filed FDA 513(g) submission for CD38 in vitro companion diagnostic.
    • What Coeptis Therapeutics Does: Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer.

    Check This Out: Investor Sentiment Declines After US Stocks Record Losses For August

    Don’t forget to check out our premarket coverage here

    ReWalk Robotics

    • The Trade: ReWalk Robotics Ltd. (NASDAQ:RWLK) Director Joseph Turk acquired a total of 1,616 shares at an average price of $0.62. The insider spent $994 to buy those shares.
    • What’s Happening: ReWalk Robotics posted downbeat quarterly results.
    • What ReWalk Robotics Does: ReWalk Robotics Ltd is an Israel based medical device company. It is engaged in designing, developing and commercializing the Rewalk systems which are exoskeletons allowing wheelchair-bound individuals to stand and walk once again.
    Get the next $BRTX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BRTX
    $COEP
    $RWLK
    $TLS

    CompanyDatePrice TargetRatingAnalyst
    Telos Corporation
    $TLS
    11/10/2023$2.75 → $4.50Neutral → Buy
    B. Riley Securities
    Telos Corporation
    $TLS
    9/27/2023$2.50 → $4.00Market Perform → Outperform
    Northland Capital
    Telos Corporation
    $TLS
    1/3/2023$5.00Outperform → Market Perform
    Northland Capital
    Telos Corporation
    $TLS
    11/15/2022$4.50 → $5.00Buy → Neutral
    B. Riley Securities
    Telos Corporation
    $TLS
    11/9/2022$15.00 → $4.00Buy → Neutral
    DA Davidson
    Telos Corporation
    $TLS
    9/12/2022$15.00Neutral → Outperform
    Wedbush
    Telos Corporation
    $TLS
    2/25/2022$14.00Outperform → Market Perform
    BMO Capital
    Telos Corporation
    $TLS
    1/19/2022$20.00Neutral → Buy
    Colliers Securities
    More analyst ratings

    $BRTX
    $COEP
    $RWLK
    $TLS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Dockery Derrick D.

    4 - TELOS CORP (0000320121) (Issuer)

    3/20/26 4:04:51 PM ET
    $TLS
    EDP Services
    Technology

    SEC Form 4 filed by Wood John B

    4 - TELOS CORP (0000320121) (Issuer)

    3/20/26 4:04:28 PM ET
    $TLS
    EDP Services
    Technology

    SEC Form 4 filed by Griffin Mark D

    4 - TELOS CORP (0000320121) (Issuer)

    3/20/26 4:04:06 PM ET
    $TLS
    EDP Services
    Technology

    $BRTX
    $COEP
    $RWLK
    $TLS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    BioRestorative Therapies to Present Positive Phase 2 Blinded Data for BRTX-100 Demonstrating Meaningful Improvements in Pain and Function in Chronic Lumbar Disc Disease

    New blinded data from ~45 patients to date in key pain and function scales and safety and tolerability of the Company's proprietary hypoxic-cultured mesenchymal stem cells to be unveiled on March 28th at the 2026 Orthopaedic Research Society Annual Meeting MELVILLE, N.Y., March 19, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative," "BRTX," or the "Company") (NASDAQ:BRTX), a late-stage clinical regenerative medicine company focused on stem cell-based therapies and products, today announced that new blinded data on approximately 45 patients from its Phase 2 clinical trial evaluating hypoxic-cultured mesenchymal stem cells for the treatment of chronic lumbar disc dise

    3/19/26 8:00:00 AM ET
    $BRTX
    Managed Health Care
    Health Care

    Telos Corporation Announces Fourth Quarter and Full Year 2025 Earnings

    ASHBURN, Va., March 16, 2026 (GLOBE NEWSWIRE) -- Telos Corporation (NASDAQ:TLS), a leading provider of cyber, cloud and enterprise security solutions for the world's most security-conscious organizations, has posted its 2025 fourth quarter and full year financial results on its investor relations website at https://investors.telos.com. Telos will host a live webcast to discuss its fourth quarter and full year 2025 financial results today, March 16, 2026, at 9:30 a.m. ET. To access the webcast, visit https://edge.media-server.com/mmc/p/p99edfa3/. Related presentation materials will be available in the Investors section of the Company's website. In addition, an archived webcast will be pos

    3/16/26 9:01:33 AM ET
    $TLS
    EDP Services
    Technology

    BioRestorative Therapies, Inc. to Participate in the Be+Well Beauty and Wellness Show in New York City, March 8-10, 2026

    Company to engage industry partners and distribution channels as part of expanding BioCosmeceutical commercialization strategy MELVILLE, N.Y., March 05, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a late stage clinical regenerative medicine innovator focused on stem cell-based therapies and products, today announced that members of its commercial leadership team will participate in the Be+Well Beauty and Wellness Show taking place March 8-10, 2026 at the Javits Center in New York City. The Be+Well trade show is one of the largest professional beauty, spa, and wellness trade events in the U.S., bringing together 35,000+

    3/5/26 8:00:00 AM ET
    $BRTX
    Managed Health Care
    Health Care

    $BRTX
    $COEP
    $RWLK
    $TLS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Telos Corporation upgraded by B. Riley Securities with a new price target

    B. Riley Securities upgraded Telos Corporation from Neutral to Buy and set a new price target of $4.50 from $2.75 previously

    11/10/23 8:14:05 AM ET
    $TLS
    EDP Services
    Technology

    Telos Corporation upgraded by Northland Capital with a new price target

    Northland Capital upgraded Telos Corporation from Market Perform to Outperform and set a new price target of $4.00 from $2.50 previously

    9/27/23 9:05:18 AM ET
    $TLS
    EDP Services
    Technology

    Telos Corporation downgraded by Northland Capital with a new price target

    Northland Capital downgraded Telos Corporation from Outperform to Market Perform and set a new price target of $5.00

    1/3/23 9:16:00 AM ET
    $TLS
    EDP Services
    Technology

    $BRTX
    $COEP
    $RWLK
    $TLS
    SEC Filings

    View All

    SEC Form DEFA14A filed by Telos Corporation

    DEFA14A - TELOS CORP (0000320121) (Filer)

    3/27/26 4:03:35 PM ET
    $TLS
    EDP Services
    Technology

    SEC Form DEF 14A filed by Telos Corporation

    DEF 14A - TELOS CORP (0000320121) (Filer)

    3/27/26 4:02:31 PM ET
    $TLS
    EDP Services
    Technology

    SEC Form 10-K filed by BioRestorative Therapies Inc.

    10-K - BioRestorative Therapies, Inc. (0001505497) (Filer)

    3/26/26 4:20:29 PM ET
    $BRTX
    Managed Health Care
    Health Care

    $BRTX
    $COEP
    $RWLK
    $TLS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Jacobs Bradley W. bought $13,400 worth of shares (4,000 units at $3.35), increasing direct ownership by 3% to 151,095 units (SEC Form 4)

    4 - TELOS CORP (0000320121) (Issuer)

    11/19/24 4:01:47 PM ET
    $TLS
    EDP Services
    Technology

    Chairman and CEO Wood John B bought $379,159 worth of shares (158,644 units at $2.39), increasing direct ownership by 3% to 5,026,925 units (SEC Form 4)

    4 - TELOS CORP (0000320121) (Issuer)

    8/14/24 4:42:54 PM ET
    $TLS
    EDP Services
    Technology

    Director Schaufeld Fredrick bought $621,494 worth of shares (250,000 units at $2.49) (SEC Form 4)

    4 - TELOS CORP (0000320121) (Issuer)

    8/14/24 4:37:56 PM ET
    $TLS
    EDP Services
    Technology

    $BRTX
    $COEP
    $RWLK
    $TLS
    Leadership Updates

    Live Leadership Updates

    View All

    BioRestorative Strengthens Commercial Leadership with Appointment of Crystal Romano as Head of Global Commercial Operations to Accelerate Growth of Cell-Based Product Portfolio

    MELVILLE, N.Y., Oct. 22, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a regenerative medicine innovator focused on stem cell-based therapies and products, today announced that Crystal Romano has joined its management team. In her role, Ms. Romano will be responsible for leading BioRestorative's global commercial operations and innovation. A seasoned executive with over 19 years of progressive leadership in the medical, aesthetics, and regenerative industries, Ms. Romano is recognized for her expertise in product development and innovation, commercialization, sales and account management, clinical and product training, a

    10/22/25 9:35:00 AM ET
    $BRTX
    Managed Health Care
    Health Care

    BioRestorative Welcomes Serial Regenerative Medicine Entrepreneur, Company Builder and Leader, Sandy Lipkins, to BRTX Team

    MELVILLE, N.Y., June 10, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a clinical stage regenerative medicine innovator focused on stem cell-based therapies and products, announced today its hiring of Industry leader, Sandy Lipkins, to focus on technology commercialization and business development, effective June 9, 2025. In his role, Mr. Lipkins will be responsible for sourcing, structuring, negotiating and executing strategic alliances and licensing/co-development agreements for BioRestorative domestically and internationally, as well as providing new product and sales expertise to the Company. Mr. Lipkins has an accom

    6/10/25 8:00:00 AM ET
    $BRTX
    Managed Health Care
    Health Care

    Coeptis Therapeutics Appoints Colleen Delaney, MD, as Chief Scientific and Medical Officer

    Dr. Delaney joins Coeptis after securing exclusive rights from Deverra Therapeutics for its allogeneic immuno-oncology platform and clinical stage programs WEXFORD, Pa., Aug. 30, 2023 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) ("Coeptis" or "the Company"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, announced that Colleen Delaney, MD, MSc, has been appointed Chief Scientific and Medical Officer of Coeptis following the completion of an exclusive rights agreement with Deverra Therapeutics for its allogeneic immuno-oncology platform and clinical stage programs.

    8/30/23 1:00:00 PM ET
    $COEP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BRTX
    $COEP
    $RWLK
    $TLS
    Financials

    Live finance-specific insights

    View All

    BioRestorative Therapies to Report Third Quarter 2025 Financial Results and Host Conference Call on November 12, 2025

    MELVILLE, N.Y., Nov. 05, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a regenerative medicine innovator focused on stem cell-based therapies and products, today announced that it will release its third quarter 2025 financial results after market close on Wednesday, November 12, 2025. Following the announcement, BioRestorative management will host a conference call to review the financial results and provide a business update. Third Quarter 2025 Results Conference Call Details: Date: Wednesday, November 12, 2025Time: 4:30 p.m. ETDomestic: 1-888-506-0062International: 1-973-528-0011Access Code: 464585 The call will also b

    11/5/25 4:30:00 PM ET
    $BRTX
    Managed Health Care
    Health Care

    BioRestorative Therapies Reports Second Quarter 2025 Financial Results and Provides Business Update

    MELVILLE, N.Y., Aug. 12, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a regenerative medicine innovator focused on stem cell-based therapies and products, today reported financial results for the second quarter ended June 30, 2025 and provided an update on its business. "We have continued to execute well across our business, including the achievement of key clinical program milestones, since the start of 2025," said Lance Alstodt, Chief Executive Officer of BioRestorative. "Moving forward, we remain focused on aggressively executing our growth strategy while carefully managing our resources, and see many potential value

    8/12/25 4:05:00 PM ET
    $BRTX
    Managed Health Care
    Health Care

    BioRestorative Therapies to Report Second Quarter 2025 Financial Results and Host Conference Call on August 12, 2025

    MELVILLE, N.Y., Aug. 05, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a clinical stage regenerative medicine innovator focused on stem cell-based therapies and products, today announced that it will release its second quarter 2025 financial results after market close on Tuesday, August 12, 2025. Following the announcement, BioRestorative management will host a conference call to review the financial results and provide a business update. Second Quarter 2025 Results Conference Call Details: Date:Tuesday, August 12, 2025Time:4:30 p.m. ETDomestic:1-888-506-0062International:1-973-528-0011Access Code:436077 The call will al

    8/5/25 4:30:00 PM ET
    $BRTX
    Managed Health Care
    Health Care

    $BRTX
    $COEP
    $RWLK
    $TLS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Coeptis Therapeutics Holdings Inc.

    SC 13G/A - Coeptis Therapeutics Holdings, Inc. (0001759186) (Subject)

    11/14/24 3:59:49 PM ET
    $COEP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13D/A filed by BioRestorative Therapies Inc. (Amendment)

    SC 13D/A - BioRestorative Therapies, Inc. (0001505497) (Subject)

    3/6/24 4:34:22 PM ET
    $BRTX
    Managed Health Care
    Health Care

    SEC Form SC 13D/A filed by BioRestorative Therapies Inc. (Amendment)

    SC 13D/A - BioRestorative Therapies, Inc. (0001505497) (Subject)

    2/15/24 4:43:54 PM ET
    $BRTX
    Managed Health Care
    Health Care